@DrChoueiri w last, very last update of #Keynote564 pembrolizumab for adjuvant #kidneycancer. Ongoing overall survival benefit — even 7+ years out.
@oncoalert #ESMO26 @myESMO

@DrChoueiri presents first biomarker work from #keynote564 — ctDNA positive group only n=60 treated but poor prognosis begs question who to escalate?? And who in neg-neg group may we de-escalate treatment? @asco #ASCO26 @oncoalert @urotoday @utswcancer